Catalyst Pharmaceutical Partners (CPRX) PT Lowered to $4.50 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 12c, Revenues Beat
May 13, 2019 6:04 AM EDTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of ($0.01), $0.12 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $12.4 million versus the consensus estimate of $1.6 million.
Total net revenue in the first quarter 2019 was $12.4 million.Selling, general and administrative expenses for the first quarter of 2019 totaled $8.4 million as compared to $2.7 million in the first quarter of 2018. The increase is primarily attributed to commercial launch expenses, as well as the patient services programs to support... More